查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1212338

新兴药品的全球市场

Pharmerging
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球新兴药品的市场规模在2022年估算为15亿美金，在2022年～2030年间预计将以9.9％的年复合成长率增长，到2030年前达到31亿美元。

本报告提供全球新兴药品市场调查，提供市场概要，市场促进因素的分析，市场机会，各地区的市场分析，竞争情形，主要企业的简介等系统性资讯。

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他的欧洲
  • 亚太地区
  • 全球其他地区

第4章 竞争

简介目录
Product Code: MCP16682

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Pharmerging Market to Reach $3.1 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Pharmerging estimated at US$1.5 Billion in the year 2022, is projected to reach a revised size of US$3.1 Billion by 2030, growing at aCAGR of 9.9% over the period 2022-2030. Pharmaceutical, one of the segments analyzed in the report, is projected to record 8.4% CAGR and reach US$1.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Healthcare segment is readjusted to a revised 12.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $430.4 Million, While China is Forecast to Grow at 9.3% CAGR

The Pharmerging market in the U.S. is estimated at US$430.4 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$540.9 Million by the year 2030 trailing a CAGR of 9.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.6% and 8.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Select Competitors (Total 22 Featured):

  • Abbott Laboratories
  • AbbVie, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Allergan PLC
  • Amgen, Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer AG
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • CSL Behring
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International PLC
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Grifols SA
  • H. Lundbeck A/S
  • Hospira, Inc.
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co., Ltd.
  • Mallinckrodt Pharmaceuticals
  • Mitsubishi Tanabe Pharma Corporation
  • Mylan Pharmaceutical Pvt. Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA
  • Shire PLC
  • Stada Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Pharmerging Market to Grow Steadily, Driven by Rapid Growth of the Pharma Sector
    • Worldwide Pharmaceutical Market Growth Projections by Regional Group: 2018 and 2022
    • Breakdown of Growth Percentage and Spending in Billion USD for Pharmerging Markets by Country: 2007-2022
    • Pharmerging - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Pharmaceutical Segment to Register Strong Growth
    • Total Spending on Medicines (in Billion USD) in Select Emerging Pharmaceutical Markets: 2023
    • Healthcare Market in Tier I Pharmerging Region (USD Billion) by Product: 2014-2025
    • Asia-Pacific Region to Retain Top Slot
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Geriatric Population to Bode Well for Market Growth
    • Total Breakdown of People Aged Over 60 by Development Groups: 1980 to 2050
    • Increase in Patient Numbers to Support Market Growth
    • Top Therapeutic Areas by Spending (Billion USD) in Pharmerging Markets: 2018
    • Select Therapy Areas Spending (Billion USD) in Pharmerging Markets: 2020
    • Increasing Preference for Generics to Spur Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Pharmerging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Pharmerging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Healthcare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for Healthcare by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 7: World Pharmerging Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 8: USA Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 9: USA 8-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2023 & 2030
  • CANADA
    • TABLE 10: Canada Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 11: Canada 8-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2023 & 2030
  • JAPAN
    • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 12: Japan Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 13: Japan 8-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2023 & 2030
  • CHINA
    • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 14: China Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 15: China 8-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2023 & 2030
  • EUROPE
    • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 16: Europe Recent Past, Current & Future Analysis for Pharmerging by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 17: Europe 8-Year Perspective for Pharmerging by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 18: Europe Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 19: Europe 8-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2023 & 2030
  • FRANCE
    • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 20: France Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: France 8-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2023 & 2030
  • GERMANY
    • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 22: Germany Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 23: Germany 8-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2023 & 2030
  • ITALY
    • TABLE 24: Italy Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 25: Italy 8-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2023 & 2030
  • UNITED KINGDOM
    • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 26: UK Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: UK 8-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 29: Rest of Europe 8-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific 8-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 32: Rest of World Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Rest of World 8-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2023 & 2030

IV. COMPETITION